Bristol-Myers Squibb Company (BMY) said Wednesday its Opdivo drug significantly increased the overall survival of patients with resectable non-small cell lung cancer combined with chemotherapy, compared to those that underwent chemotherapy only.
This was from the company's analysis of the results of its phase 3 Checkmate -816 study, which was a key secondary endpoint of the study. It also builds on the successful primary endpoints of the study with regard to event-free survival and pathological complete response.
Opdivo is a programmed death-1 immune checkpoint inhibitor that is designed to use the body's own immune system to help restore anti-tumor immune response.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。